As our data indicated that the loss of ARID1A promotes the expression of interferon‐stimulated genes (ISGs), and limited accessibility and impaired expression of ISGs was found to correlate with poor immunotherapy response in ovarian clear cell carcinoma [21], we speculate that ARID1A‐negative tumors may be particularly sensitive to immunotherapy. The gene discussed is STING1; the disease is ovarian clear cell cancer.